Previous 10 | Next 10 |
Compugen ( CGEN ) Q3 results : Revenues: $0; R&D Expense: $4.3M (-44.9%); SG&A: $2.4M (-11.1%); Net loss: ($6.5M) (-109.7%); loss/share: ($0.10) (-100.0%); Quick Assets: $47.6M (+4.2%). More news on: Compugen Ltd., Healthcare stocks news, Earnings news and commentary, Stocks on th...
Compugen (NASDAQ: CGEN ): Q3 GAAP EPS of -$0.10 in-line. More news on: Compugen Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
HOLON, Israel , Nov. 11, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the third quarter ended September 30, 2019 . "Our first presen...
HOLON, Israel , Nov. 6, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted a new patent covering the composition of matter and ...
HOLON, ISRAEL , Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preclinical results from its COM902 anti-TIGIT program supporting its potential cli...
HOLON, Israel , Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ongoing Phase 1 dose escalation study of COM701, a first-...
HOLON, ISRAEL , Nov. 4, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared its investigational new drug (IND...
HOLON, Isreal, Oct. 28, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2019 financial results on Monday, November...
HOLON, Israel , Oct. 2, 2019 /PRNewswire/ -- October 2, 2019 – Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced it will present three posters at the 34 th Annual Meeting of the Socie...
HOLON, Israel , Sept. 19, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced progress in its ongoing Phase 1 clinical study evaluating COM701, a first-in-class therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...